Brand and Other Names:Faslodex
Dosing & Uses
Dosage Forms & Strengths
- Indicated for hormone receptor (HR) positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy
- 500 mg IM on days 1, 15, 29, then once monthly thereafter
Combination with palbociclib
- Indicated for HR-positive, (HER2)-negative advanced or metastatic breast cancer in combination with palbociclib in women (regardless of menopausal status) with disease progression after endocrine therapy
- Fulvestrant 500 mg IM on days 1, 15, 29, and once monthly thereafter
- Palbociclib starting dose: 125 mg PO qDay with food x21 days followed by 7 days off therapy to comprise a complete cycle of 28 days
- Pre/perimenopausal women treated with the palbociclib combination should be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards
- Moderate hepatic impairment (Child-Pugh class B): 250 mg IM on days 1, 15, 29, then once monthly thereafter
- Severe impairment: Not studied
Dosage Forms & Strengths
Precocious Puberty (Off-label)
Indicated in females for progressive precocious puberty associated with McCune-Albright syndrome
- Dose adjustment may be required, although no specific recommendations defined for children with hepatic impairment (in adults with Child-Pugh class B, the dose is decreased by 50%)
Serious - Use Alternative
Significant - Monitor Closely
Back pain (14%)
Abd pain (12%)
Inj site pain (11%)
Peripheral edema (9%)
Chest pain (7%)
Flu-like syndrome (7%)
Hypersensitivity reactions including angioedema and urticaria
Vaginal bleeding (mainly during the first 6 weeks after changing from existing hormonal therapy)
Elevated bilirubin, gamma GT, hepatitis, and liver failure
Hypersensitivity to fulvestrant or any component of formulation
Caution in bleeding diathesis, thrombocytopenia, therapeutic anticoagulation
Hepatic impairment; decrease dose to 250 mg dose with moderate hepatic impairment (Child-Pugh class B)
Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception; see Pregnancy section
Therapy can interfere with estradiol measurement by immunoassay, resulting in falsely elevated estradiol levels
Injection site related events including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy reported
Pregnancy & Lactation
Based on findings from animal studies and its mechanism of action, fulvestrant can cause fetal harm when administered to a pregnant woman
In animal reproduction studies, administration of fulvestrant to pregnant rats and rabbits during organogenesis resulted in embryo-fetal toxicity at daily doses that are significantly less than the maximum recommended human dose
Advise pregnant women of the potential risk to a fetus
Advise females of reproductive potential to use effective contraception during treatment and for 1 year after the last dose
Excretion in human milk unknown; do not breastfeed
Pregnancy Category: D
Lactation: excretion in milk unknown; contraindicated
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Breast cancer: Competitively binds to estrogen receptors on tumors and other tissue targets, producing nuclear complex that decreases DNA synthesis and inhibits estrogen effects; no estrogen-receptor agonist activity; downregulates estrogen receptors and inhibits breast tumor growth
Precocious puberty (off-label): Estrogen receptor antagonist
Peak Plasma Time: 7 days
Duration: Plasma levels detected for 1 month
Protein Bound: 99%
Vd: 3-5 L/kg
Via multiple hepatic pathways
Half-Life: 40 days
Excretion: Feces >90%; urine <1%
Administer IM in buttocks slowly (over 1-2 minutes per injection) as two 5-mL (250 mg) injections, on in each buttock (or one 5-mL IM injection for moderate hepatic impairment)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs